Compare DexCom, Inc. (DXCM) vs Dyne Therapeutics Inc. Common Stock (DYN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Dyne Therapeutics Inc. Common Stock — how do they compare? DexCom, Inc. trades at $86.94 (market cap $31.51B), while Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B). The key difference: DexCom, Inc. is far larger — about 11.2× Dyne Therapeutics Inc. Common Stock's market cap, and DexCom, Inc. is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Dyne Therapeutics Inc. Common Stock for 0 Days on average.
| DXCM | DYN | |
|---|---|---|
Market Cap | $31.51B | $2.81B |
Volume | 3,480,291 | 2,195,902 |
Sector | Health | Health |
52-Week High | $92.34 | $26.78 |
52-Week Low | $54.84 | $14.60 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $30.96B | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $85.06, down 1.0% on the day, with a bullish technical signal and strong fundamental growth. Revenue reached $4.66B in 2025 with a net income margin of 17.93%, and the company has beaten EPS estimates for the last three quarters. Recent news highlights expansion in Type 2 diabetes care and executive promotions, supporting positive sentiment.
The outlook is positive with a consensus price target of $96.14, implying 13% upside. Risks include competition and reimbursement challenges, but robust earnings growth and institutional backing provide a solid foundation for long-term investors.
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →
